Seer's Core Proteomics Patent Upheld by PTAB Against Competitor Challenge

summarizeSummary

Seer, Inc. announced that the Patent Trial and Appeal Board (PTAB) upheld 23 claims of its key patent covering the Proteograph platform, successfully defending against a challenge from Bruker Corporation subsidiaries.

check_boxKey Events

• Key Patent Claims Upheld

  The Patent Trial and Appeal Board (PTAB) issued a Final Written Decision on March 23, 2026, upholding 23 claims of U.S. Patent No. 11,435,360 B2. This includes 5 challenged claims and 18 unchallenged claims, which remain valid and enforceable.

• Defense Against Competitor Challenge

  The patent review was initiated by PreOmics GmbH and Biognosys AG, both subsidiaries of Bruker Corporation, challenging 11 claims of the '360 patent. Seer successfully defended the majority of the challenged claims.

• Protection of Core Technology

  The upheld patent claims cover methods for analyzing biological samples using engineered nano- and microparticles for protein enrichment, which is fundamental to Seer's Proteograph platform for deep proteomic analysis.

• Appeal Period Noted

  Either party has until May 25, 2026, to file a notice of appeal regarding the PTAB's decision.

auto_awesomeAnalysis

This 8-K announces a significant legal victory for Seer, Inc., as the Patent Trial and Appeal Board (PTAB) upheld 23 claims of its foundational U.S. Patent No. 11,435,360 B2. This patent is crucial as it protects the company's proprietary nano- and microparticle protein enrichment technology, which underpins its Proteograph platform. The successful defense against a challenge from Bruker Corporation subsidiaries, PreOmics GmbH and Biognosys AG, reinforces Seer's competitive position and intellectual property moat in the proteomics market. While some claims were deemed unpatentable, the majority of the patent's scope remains intact, providing stability and confidence in the company's core technology, especially as the stock trades near its 52-week low.